Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D

Annals of Neurology

Volumn 68, Issue 5, 2010, Pages 629-638

  Mendell, Jerry R ^a,b   Rodino Klapac, Louise R ^a,b   Rosales, Xiomara Q ^b   Coley, Brian D ^a   Galloway, Gloria ^a,b   Lewis, Sarah ^b   Malik, Vinod ^b   Shilling, Chris ^b   Byrne, Barry J ^c,d   Conlon, Thomas ^c,d   Campbell, Katherine J ^b   Bremer, William G ^b   Taylor, Laura E ^b   Flanigan, Kevin M ^a,b   Gastier Foster, Julie M ^e   Astbury, Caroline ^e   Kota, Janaiah ^b   Sahenk, Zarife ^a,b   Walker, Christopher M ^a,b   Clark, K Reed ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e Department of Pathology and Laboratory Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SARCOGLYCAN; AZITHROMYCIN; CASPASE 3; CREATINE KINASE MM; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY TITER; APOPTOSIS; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSPOT ASSAY; EXTENSOR DIGITORUM LONGUS MUSCLE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE TRANSFER; GENOME; HUMAN; INFLAMMATORY CELL; LIMB GIRDLE MUSCULAR DYSTROPHY; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE D; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MONONUCLEAR CELL; MUSCLE CELL; NICK END LABELING; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE; SORE THROAT; STREPTOCOCCUS INFECTION; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM; WBC COU;

ADOLESCENT; ADULT; APOPTOSIS; CHILD; DEPENDOVIRUS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; SARCOGLYCANS;

EID: 78249253608     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22251     Document Type: Article

References (19)

1. Herzog RW, Cao O, Srivastava A., Two decades of clinical gene therapy-success is finally mounting. Discov Med 2010; 9: 105 - 111.
2. Wang B, Li J, Fu FH, et al. Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther 2008; 15: 1489 - 1499.
3. Hauser MA, Robinson A, Hartigan-O'Conner D, et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol Ther 2000; 2: 16 - 25.
4. Laval SH, Bushby KM., Limb-girdle muscular dystrophies-from genetics to molecular pathology. Neuropathol Appl Neurobiol 2004; 30: 91 - 105.
5. Carrié A, Piccolo F, Leturcq F., Mutational diversity and hot spots in the alpha-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D). J Med Genet 1997; 34: 470 - 475.
6. Bönnemann CG, Finkel RS., Sarcolemmal proteins and the spectrum of limb-girdle muscular dystrophies. Semin Pediatr Neurol 2002; 9: 81 - 99.
7. Mendell JR, Rodino-Klapac L, Rosales-Quintero X, et al. Limb girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 2009; 66: 290 - 297.
8. Reese, MG., Application of a time-delay neural network to promoter annotation in the Drosophila melanogaster genome. Comput Chem 2001; 26: 51 - 56.
9. Johnson PR, Schnepp BC, Connell MJ, et al. Novel adeno associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005; 79: 955 - 965.
10. Chen C-L, Jensen RL, Schnepp BC, et al. Molecular characterization of adeno-associated viruses infecting children. J Virol 2005; 79: 14781 - 14792.
11. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006; 12; 342 - 347.
12. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity revealed by gene therapy in Duchenne muscular dystrophy. N Engl J Med (in press).
13. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791 - 801.
14. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342 - 347.
15. Chahin N, Engel AG., Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70: 418 - 424.
16. Wylie AH., -Where, O Death, Is Thy Sting?- A brief review of apoptosis biology. Mol Neurobiol 2010; 42: 4 - 9.
17. Pacak CA, Conlon T, Mah CS, Byrne BJ., Relative persistence of AAV serotype 1 vector genomes in dystrophic muscle. Genet Vaccines Ther 2008; 6: 14.
18. Pacak CA, Walter GA, Gaidosh G, et al. Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol Ther 2007; 15: 1775 - 1781.
19. Rodino-Klapac LR, Montgomery CL, Bremer WG, et al. Persistent expression of FLAG tagged micro-dystrophin in non-human primates with intramuscular and vascular approaches. Mol Ther 2010; 18: 109 - 117.